HR+ breast cancers have the best prognosis and can be treated with tamoxifen, an ER antagonist, fulvestrant, which directly hampers ER synthesis, and aromatase inhibitors, namely, anastrozole, exemestane, and letrozole [47]. The gene discussed is CYP19A1; the disease is breast carcinoma.